TimothySFenskeMDMS

Oncology • Milwaukee, WI

Hematologic Oncology

Professor of Medicine

Join to view full profile

Dr. Fenske is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Fenske's full profile

Already have an account?

Office
Froedtert / MCW Clinical Cancer Center
9200 West Wisconsin Avenue
Milwaukee, WI 53226
Phone+1 414-805-4633

Fax+1 414-805-4606

Education & Training

Washington University/B-JH/SLCH ConsortiumFellowship, Hematology and Medical Oncology, 2002 - 2005
University of Wisconsin Hospitals and ClinicsResidency, Internal Medicine, 1999 - 2002
University of Wisconsin School of Medicine & Public HealthClass of 1999

Certifications & Licensure

WI State Medical License 2000 - 2025
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Murphy Award for Clinical Excellence Medical College of WI, Dept of Medicine, 2012
CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013

Clinical Trials

Rituxan/BEAM vs Bexxar/BEAM in Autologous Hematopoietic Stem Cell Transplant for Non-Hodgkin's Lymphoma (BMTCTN0401) Start of enrollment: 2005 Dec 01
Completed
Phase 3
Blood Stem Cell Transplant With Low Dose Chemotherapy for Relapsed Follicular Non-Hodgkin's Lymphoma (BMT CTN 0701) Start of enrollment: 2009 Apr 01
Completed
Phase 2
Combination Chemotherapy in Treating Patients With Non-Metastatic Extracranial Ewing Sarcoma Start of enrollment: 2010 Nov 22
Active, not recruiting
Phase 3
Study of Velcade and Temsirolimus for Relapsed or Refractory Non-Hodgkin Lymphoma Start of enrollment: 2011 Feb 01
Completed
Phase 2
Efficacy and Safety of Idelalisib (GS-1101) in Combination With Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas Start of enrollment: 2013 Jan 16
Terminated
Phase 3
Efficacy and Safety of Idelalisib (GS-1101) in Combination With Bendamustine and Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas Start of enrollment: 2013 Jan 02
Terminated
Phase 3
Rituximab and Combination Chemotherapy With or Without Lenalidomide in Treating Patients With Newly Diagnosed Stage II-IV Diffuse Large B Cell Lymphoma Start of enrollment: 2013 Aug 27
Active, not recruiting
Phase 2
Brentuximab Vedotin and Nivolumab With or Without Ipilimumab in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma Start of enrollment: 2014 Mar 07
Suspended
Phase 1, Phase 2
Rituximab With or Without Stem Cell Transplant in Treating Patients With Minimal Residual Disease-Negative Mantle Cell Lymphoma in First Complete Remission Start of enrollment: 2018 Mar 06
Recruiting
Phase 3
Safety and Preliminary Efficacy of JBH492 Monotherapy in Patients With CLL and NHL Start of enrollment: 2020 Sep 07
Active, not recruiting
Phase 1
Join now to see all

Publications & Presentations

PubMed

9 citations
Long-term outcomes and predictors of early response, late relapse, and survival for patients treated with bispecific LV20.19 CAR T-cells.
Joanna C Zurko, Timothy S Fenske, Bryon D Johnson, Daniel Bucklan, Aniko Szabo
American Journal of Hematology. 2022-12-01
269 citations
Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell malignancies: a phase 1 dose escalation and expansion trial
Nirav N. Shah, Bryon D. Johnson, Dina Schneider, Fenlu Zhu, Aniko Szabo
Nature Medicine. 2020-10-05
15 citations
Impact of type of reduced-intensity conditioning regimen on the outcomes of allogeneic haematopoietic cell transplantation in classical Hodgkin lymphoma.
Sairah Ahmed, Nilanjan Ghosh, Kwang Woo Ahn, Manoj Khanal, Carlos Litovich
British Journal of Haematology. 2020-04-21

Abstracts/Posters

Short Time to Treatment Is Associated with Inferior Survival in Newly Diagnosed Patients with Mantle Cell Lymphoma
Timothy S. Fenske, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Comparison of Reduced-Intensity Conditioning (RIC) Regimens for Allogeneic Hematopoietic Cell Transplantation (alloHCT) for Classical Hodgkin Lymphoma (cHL):a Center f...
Timothy S. Fenske, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Comparison of Reduced-Intensity Conditioning (RIC) Regimens for Allogeneic Hematopoietic Cell Transplantation (alloHCT) in Non-Hodgkin Lymphomas (NHL)-a Center for Int...
Timothy S. Fenske, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Clinical Trial Participation Is Associated with Improved Overall Survival in Newly Diagnosed Patients with Mantle Cell Lymphoma
Timothy S. Fenske, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Outcomes Following Early Relapse in Patients with Mantle Cell Lymphoma
Timothy S. Fenske, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Maintenance Rituximab Improves Outcomes in Mantle Cell Lymphoma Patients Who Respond to Induction Therapy with Bendamustine + Rituximab without Autologous Transplant
Timothy S. Fenske, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Fresh Versus Cryopreserved/Thawed Bispecific Anti-CD19/CD20 CAR-T Cells for Relapsed, Refractory Non-Hodgkin Lymphoma
Timothy S. Fenske, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Does Addition of Rituximab (R) to BEAM Conditioning Improve Outcomes of Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Undergoing Autologous Hematopoietic Cell Tr...
Timothy S. Fenske, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Join now to see all

Lectures

Five-Year Outcomes of SWOG S0: A Randomized Phase II US Intergroup Study of R-HCVAD Vs. R-Bendamustine Followed By Autologous Stem Cell Transplant for Patients with Ma...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Press Mentions

Combination Immunotherapy Shows High Activity Against Recurrent Hodgkin LymphomaDecember 3rd, 2018
Newly Diagnosed Mantle Cell Lymphoma Is ‘One of the Hardest Consultations’April 21st, 2017